News Center
Shanghai Pharma Ranks Second among the Top 100 Enterprises in China’s Pharmaceutical Industry and Tops the List of Top 20 Pharmaceutical Enterprises with the Most Brand Competitiveness in China

    On June 30, the 2015 National Pharmacy Week and the 10th Annual Meeting of Top 100 Enterprises in China’s Pharmaceutical Industry was held in Tengchong, Yunnan. At the Meeting, such awards as “Top 100 Enterprises in China’s Pharmaceutical Industry 2014” and “Top 20 Pharmaceutical Enterprises with the Most Brand     Competitiveness in China” were officially released. Shanghai Pharma ranked second among the Top 100 Enterprises in China’s Pharmaceutical Industry, up one place from 2013, and topped the List of Top 20 Pharmaceutical Enterprises with the Most Brand Competitiveness in China with a comprehensive value of 98.6.

    Lou Dingbo, Chairman and Party Secretary of Shanghai Pharma, gave a speech as a representative of the top 100 entrepreneurs in China’s pharmaceutical industry. Lou Dingbo expressed congratulations on the convening of the meeting, and thanked the Annual Meeting of Top 100 Enterprises in China’s Pharmaceutical Industry for providing industry participants with an exchange platform. Shanghai Pharma, as a large comprehensive pharmaceutical industry group with complete industrial chain, ranked second in China’s pharmaceutical industry and has made the List of Top 100 Enterprises in China’s Pharmaceutical Industry for ten straight years.

    Lou Dingbo pointed out that it has been well known that Shanghai Pharma embraces innovation. This year, Shanghai Pharma accelerated the “Internet+” strategic layout, and set up e-commerce company for entering prescription medicine O2O selling quickly with this platform. Later on, we launched comprehensive strategic cooperation with Jingdong in terms of strategy, capital, business, etc. In the context of Internet+, we actively explored new business mode, took the initiative to “touch internet” and deeply dug the value of product and customer experience. The R&D and industrialization base project of Shanghai Pharma Group (Benxi) Beifang Pharmaceutical Co., Ltd. was started recently. With Beifang Pharmaceutical as the platform, internationally compatible high-end APIs and drug products industrialization base would be built, which would effectively solve R&D bottlenecks; at the same time, with this link, we intensified the cooperation with relevant universities and colleges to further achieve the synergy of production, learning and research and vigorously promote R&D innovation, achievement transformation, and industrialization connection. Facing the new normal, Shanghai Pharma will continue to advance in an orderly fashion according to the set development strategy of “three-year basic development, six-year climbing development and nine-year soaring development”, actively learn from the global industry development experience with an open and inclusive attitude, constantly expand industry boundary, innovate industrial organization form, and promote sustainable development. Shanghai Pharma hoped to innovate with counterparts to boost new level of industry development together.

    According to reports, the selection of “Top 100 Enterprises in China’s Pharmaceutical Industry” was guided by CFDA South Medical Economics Institute and initiated by Medical Economics, and the statistical indicator of the selection was enterprise’s annual pharmaceutical industry sales revenue (the statistics was made based on Chinese accounting standards). In recent ten years, the scale growth and profit increase of top 100 enterprises have been higher than the industry average stably, and the  concentration degree of top 100 enterprises has been improving.

    The selection of “Top 20 Pharmaceutical Enterprises with the Most Brand Competitiveness in China” was conducted by reference to the evaluation method of “the World’s 500 Most Valuable Brands” adopted by the World Brand Laboratory. The brand competitiveness index of pharmaceutical enterprises was comprehensively evaluated from four dimensions: finance operating force, market competitiveness, brand growth potential, public support. The concentrated features of the top 20 pharmaceutical enterprises with the most brand competitiveness are as follows: pharmaceutical enterprise brand with benign expansion of brand life cycle, some achievements in brand expansion, especially development from simple pharmaceutical enterprise to medical large health group, and penetration to diversified on-line channels from single off-line channels.

    In addition, the “List of Top 100 Chain Drugstores with the Best Comprehensive Strength in China” list was released at the meeting, and Shanghai Huashi Pharmacy, a subsidiary of Shanghai Pharma, ranked No.8 on the list.

 

The subject of concern
Produced By 大汉网络 大汉版通发布系统